Company profile / PTCT

PTC Therapeutics

Clinaptis stanceNeutral

ConvictionLow

Ticker: PTCT
Exchange: NASDAQ
Coverage: Standard profile
Updated: Aug 19, 2026

Rare Disease / Neurology

Global biopharmaceutical company focused on rare diseases, with a commercial portfolio and pipeline spanning metabolic, neurological, and neuromuscular disorders.

01 / Clinaptis view

Structured view under review

This company remains in the coverage universe while the structured company view is being completed.

02 / Consensus gap

Assessment under review

The evidence-versus-expectation assessment has not yet been published for this profile.

Coverage state: Standard profile

What the review turns on

Key variable

Commercial persistence

Next catalyst

Vatiquinone · PROVE-FA study initiation supporting NDA resubmission · Q3 2026

03 / Pipeline

Key programs

2 assets · 2 programs

AssetIndicationStageNext event

Evrysdi (risdiplam)

Spinal muscular atrophy

Commercial / Partnered

Ongoing Roche commercial sales and PTC royalty revenue

Vatiquinone

Friedreich's ataxia

NDA resubmission-enabling development

PROVE-FA study initiation expected Q3 2026

04 / Connected research

Published on PTCT

View full archive

No published research attached

The profile is live. The research connection is still open.

When a Clinaptis article includes PTCT in its research metadata, it will appear here automatically.

Browse all research